source
- Celldex culls eczema study after Phase 2 failureCelldex Therapeutics is dropping its monoclonal antibody as a therapy for eczema after the drug flunked a mid-stage study. The drug, called barzolvolimab, failed to reduce itching in patients with…Endpoints · 54m ago↗ source
- CNS dispatches from Jefferies: Acadia’s search for deals, Alto’s psychiatry question and ProMIS’ Alzheimer’s ambitionsThe chaotic environs of this year’s Jefferies Healthcare conference, held earlier this week in London, attracted a number of drugmakers active in the central nervous system (CNS) and psychiatry spa…Endpoints · 1h ago↗ source
- Teva on the hunt for new R&D head; Summit's rejection came after commercial chief's exit→ Teva’s global R&D leader and CMO Eric Hughes has stepped down and David Gardiner is replacing him on an interim basis. Hughes came to Teva in 2022 from Vertex, where he was SVP of ...